On Wednesday, People’s United Financial, Inc. (NASDAQ:PBCT)’s shares declined -0.99% to $15.97.
People’s United Financial, Inc. (PBCT) declared recently it will release its second quarter financial results on Thursday, July 16 at about 4 p.m. Eastern Time. The company will host a conference call the same day at 5:00 p.m. Eastern Time to talk about its second quarter 2015 earnings declarement.
The call will be broadcast live through the company’s Internet site, peoples.com. It is accessible by selecting “Investor Relations” in the “About Us” section on the home page, and then selecting “Conference Call” in the “News and Events” section.
Peoples United Financial, Inc. operates as the bank holding company for People’s United Bank that provides commercial banking, retail banking, and wealth administration services to individual, corporate, and municipal customers. The company operates through two segments, Commercial Banking and Retail Banking. The Commercial Banking segment principally comprises of commercial real estate lending, commercial and industrial lending, and commercial deposit gathering activities.
Jabil Circuit, Inc. (NYSE:JBL)’s shares dropped -1.10% to $24.32.
Jabil Circuit, Inc. (JBL)’s senior vice president, sales enablement and marketing, Joanne Moretti, has been named a gold winner in the Women World Awards in the manufacturing category.
The Women World Awards were created to honor and generate industry-wide recognition of achievements and positive contributions of working women at every level and every industry from around the world. The program recognizes the world’s best in leadership, innovation, organizational performance, new products and services, women case studies, and customer satisfaction programs from every major industry. Organizations from all over the world are eligible to submit nominations counting public and private, for-profit and non-profit, largest to smallest and new start-ups.
Jabil Circuit, Inc., together with its auxiliaries, provides electronic manufacturing services and solutions worldwide. It offers electronics design, production, and product administration services to companies in the aerospace, automotive, computing, defense, digital home, energy, healthcare, industrial, instrumentation, lifestyles, mobility, mold, networking, packaging, peripherals, storage, telecommunications, and wearable technology industries .
At the end of Wednesday’s trade, Ocata Therapeutics Inc (NASDAQ:OCAT)‘s shares dipped -15.09% to $5.29.
Ocata Therapeutics Inc (OCAT) a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology™, recently declared the pricing of an underwritten offering of 5,500,000 shares of its common stock together with accompanying warrants to purchase an aggregate of 2,750,000 shares of common stock. The combined offering price of each share of common stock and accompanying warrant was $5.50. The gross proceeds to Ocata Therapeutics from this offering are predictable to be $30.25 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Ocata Therapeutics. The warrants will be exercisable at $7.48 per share, will be exercisable starting on December 22, 2015 and will expire on December 22, 2020. The shares of common stock and warrants are right away separable and will be issued separately. Ocata Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock and/or warrants to purchase 412,500 shares of common stock to cover over-allotments, if any. Ocata Therapeutics intends to use the net proceeds from the sale of the offered securities to fund its clinical activities, counting the commencement of its Phase 2 AMD and pivotal SMD clinical trials, the advancement of its pre-clinical studies in other ocular indications and other programs, and for general corporate purposes, which may comprise, but are not limited to, working capital, potential business development activities, ongoing research and development activities, funding regulatory approval application processes, and capital expenditures.
Ocata Therapeutics, Inc., a clinical stage biotechnology company, develops and commercializes regenerative ophthalmology therapeutics in the United States. The company is conducting various clinical trials for treating Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration, in addition to pre-clinical trials for the treatment of other ocular disorders; and has pre-clinical stage assets in disease areas outside the field of ophthalmology, counting autoimmune, inflammatory, and wound healing-related disorders.
Sanofi SA (ADR) (NYSE:SNY), ended its Wednesday’s trading session with -0.83% loss, and closed at $48.81.
Sanofi SA (ADR) (SNY) and Regeneron Pharmaceuticals, Inc. declared that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the investigational therapy Praluent® (alirocumab) Injection. The Committee voted 13 to 3 (with no abstentions) that Sanofi and Regeneron had sufficiently established that the low-density lipoprotein cholesterol (LDL-C, or bad cholesterol) lowering benefit of Praluent exceeds its risks to support approval in one or more patient populations.
The Committee’s recommendation was based on Praluent’s benefit-risk profile, following review of efficacy and safety data from more than 5,000 patients across 10 pivotal Phase 3 double-blind trials ranging from six months to two years. Clinical data from the ODYSSEY Phase 3 program show comprising, positive results in reducing LDL-C. Common adverse events that were more frequently stated in patients treated with Praluent than the control groups comprised of injection site reaction and pruritus (itching).
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
